Company profile
INOVIO PHARMACEUTICALS, INC.
NASDAQ:INOBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BIZALIMOGENE RALAPLASMID | phase3 | — | 7 | no active trials |
| RELUSCOVTOGENE RALAPLASMID | phase2_3 | — | 3 | completed, terminated, withdrawn |
| ROCAKINOGENE SIFUPLASMID | phase1_2 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01403155 | phase1 | completed | 2011-05-01 | 2012-08-01 | Inovio Pharmaceuticals | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 |
| NCT01405885 | phase1 | completed | 2011-05-01 | 2013-08-01 | Inovio Pharmaceuticals | A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus |
| NCT02172911 | phase1_2 | completed | 2014-06-06 | 2017-09-07 | Inovio Pharmaceuticals | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer |
| NCT01304524 | phase2 | completed | 2011-04-01 | 2014-05-01 | Inovio Pharmaceuticals | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 |
| NCT04093076 | phase1 | completed | 2021-01-27 | 2022-10-14 | Inovio Pharmaceuticals | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana |
FDA applications (0)
No records yet.